{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:00:25Z","timestamp":1789124425672,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3469-y","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T13:20:51Z","timestamp":1542201651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0439-8162","authenticated-orcid":false,"given":"Jos\u00e9 \u00c1ngel","family":"Cuenca-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Lozano-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Cabezas-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Jes\u00fas","family":"Soriano-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"V\u00e1zquez-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Est\u00e9vez-Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cabeza-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Salas-Coronas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"3469_CR1","unstructured":"WHO. Hepatitis B: WHO; 2018 [cited 2018 10-08-2018]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/es\/ ."},{"issue":"10","key":"3469_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005842","volume":"11","author":"GA O'Hara","year":"2017","unstructured":"O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl Trop Dis. 2017;11(10):e0005842.","journal-title":"PLoS Negl Trop Dis"},{"key":"3469_CR3","volume-title":"WHO","author":"WHO","year":"2017","unstructured":"WHO. Global hepatitis report, 2017. In: WHO; 2017."},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.meegid.2013.03.021","volume":"16","author":"W Shi","year":"2013","unstructured":"Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, et al. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections Infection, genetics and evolution. Journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2013;16:355\u201361.","journal-title":"Journal of molecular epidemiology and evolutionary genetics in infectious diseases"},{"issue":"6","key":"3469_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","volume":"67","author":"N Rajoriya","year":"2017","unstructured":"Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. time for an individualised approach? J Hepatol. 2017;67(6):1281\u201397.","journal-title":"J Hepatol"},{"issue":"12","key":"3469_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1136\/gut.2008.157149","volume":"57","author":"HW Zhang","year":"2008","unstructured":"Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut. 2008;57(12):1713\u201320.","journal-title":"Gut"},{"issue":"4","key":"3469_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2893.1999.00174.x","volume":"6","author":"C Mayerat","year":"1999","unstructured":"Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat. 1999;6(4):299\u2013304.","journal-title":"J Viral Hepat"},{"issue":"1","key":"3469_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s535-002-8130-z","volume":"37","author":"M Kobayashi","year":"2002","unstructured":"Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes a, B, and C. J Gastroenterol. 2002;37(1):35\u20139.","journal-title":"J Gastroenterol"},{"issue":"1","key":"3469_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/jmv.20320","volume":"76","author":"Y Suzuki","year":"2005","unstructured":"Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype a and treatment in Japan. J Med Virol. 2005;76(1):33\u20139.","journal-title":"J Med Virol"},{"issue":"7","key":"3469_CR10","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1053\/gast.2002.33588","volume":"122","author":"CJ Chu","year":"2002","unstructured":"Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122(7):1756\u201362.","journal-title":"Gastroenterology"},{"issue":"5","key":"3469_CR11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","volume":"133","author":"SE Livingston","year":"2007","unstructured":"Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes a, B, C, D, and F. Gastroenterology. 2007;133(5):1452\u20137.","journal-title":"Gastroenterology"},{"issue":"1","key":"3469_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","volume":"125","author":"C Westland","year":"2003","unstructured":"Westland C, Delaney WT, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107\u201316.","journal-title":"Gastroenterology"},{"issue":"4","key":"3469_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jnci\/dji043","volume":"97","author":"MW Yu","year":"2005","unstructured":"Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265\u201372.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3469_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1128\/JCM.40.1.22-25.2002","volume":"40","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol. 2002;40(1):22\u20135.","journal-title":"J Clin Microbiol"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/1471-2334-13-328","volume":"13","author":"M Yousif","year":"2013","unstructured":"Yousif M, Mudawi H, Bakhiet S, Glebe D, Kramvis A. Molecular characterization of hepatitis B virus in liver disease patients and asymptomatic carriers of the virus in Sudan. BMC Infect Dis. 2013;13:328.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"3469_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jhep.2005.03.018","volume":"43","author":"CM Chu","year":"2005","unstructured":"Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43(3):411\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"3469_CR17","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1053\/gast.2002.37041","volume":"123","author":"JM Sanchez-Tapias","year":"2002","unstructured":"Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002;123(6):1848\u201356.","journal-title":"Gastroenterology"},{"issue":"1","key":"3469_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1086\/509894","volume":"195","author":"SE Livingston","year":"2007","unstructured":"Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5\u201311.","journal-title":"J Infect Dis"},{"issue":"16","key":"3469_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnci\/djn243","volume":"100","author":"HI Yang","year":"2008","unstructured":"Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(16):1134\u201343.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3469_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/jmv.20311","volume":"75","author":"MC Kew","year":"2005","unstructured":"Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype a in bantu-speaking sub-saharan Africans. J Med Virol. 2005;75(4):513\u201321.","journal-title":"J Med Virol"},{"key":"3469_CR21","first-page":"A1436","volume":"54","author":"PVM Lampertico","year":"2011","unstructured":"Lampertico PVM, Soffredini R. Entecavir monotherapy for nuc-na\u20ac\u0131ve chronic hepatitis B patients from field practice: high efficacy and favorable 0safety profile over 3 year. Hepatology. 2011;54:A1436.","journal-title":"Hepatology"},{"issue":"3","key":"3469_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57(3):508\u201314.","journal-title":"J Hepatol"},{"issue":"5","key":"3469_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","volume":"62","author":"R Zoutendijk","year":"2013","unstructured":"Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62(5):760\u20135.","journal-title":"Gut"},{"issue":"6","key":"3469_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s11096-015-0193-1","volume":"37","author":"JH Kim","year":"2015","unstructured":"Kim JH, Jung SW, Byun SS, Shin JW, Park BR, Kim MH, et al. Efficacy and safety of tenofovir in nucleos(t)ide-naive patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm. 2015;37(6):1228\u201334.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"3469_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4254\/wjh.v9.i1.48","volume":"9","author":"GC Lovett","year":"2017","unstructured":"Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, et al. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol. 2017;9(1):48\u201356.","journal-title":"World J Hepatol"},{"issue":"3","key":"3469_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195045","volume":"13","author":"V Malagnino","year":"2018","unstructured":"Malagnino V, Salpini R, Maffongelli G, Battisti A, Fabeni L, Piermatteo L, et al. High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. PLoS One. 2018;13(3):e0195045.","journal-title":"PLoS One"},{"issue":"1","key":"3469_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3851\/IMP3055","volume":"22","author":"TN Archampong","year":"2017","unstructured":"Archampong TN, Boyce CL, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, et al. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients. Antivir Ther. 2017;22(1):13\u201320.","journal-title":"Antivir Ther"},{"issue":"3","key":"3469_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.13156","volume":"31","author":"A Boyd","year":"2016","unstructured":"Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholie SP, et al. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from sub-Saharan Africa. J Gastroenterol Hepatol. 2016;31(3):634\u201344.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"3469_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3851\/IMP2959","volume":"20","author":"A Boyd","year":"2015","unstructured":"Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, et al. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from cote d'Ivoire. Antivir Ther. 2015;20(6):643\u201354.","journal-title":"Antivir Ther"},{"issue":"6","key":"3469_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099971","volume":"9","author":"BL Honge","year":"2014","unstructured":"Honge BL, Jespersen S, Medina C, Te Dda S, da Silva ZJ, Lewin S, et al. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One. 2014;9(6):e99971.","journal-title":"PLoS One"},{"issue":"1","key":"3469_CR31","first-page":"29","volume":"38","author":"MA De Francesco","year":"2015","unstructured":"De Francesco MA, Gargiulo F, Spinetti A, Zaltron S, Giagulli C, Caccuri F, et al. Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine. The new microbiologica. 2015;38(1):29\u201337.","journal-title":"The new microbiologica"},{"issue":"11","key":"3469_CR32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/jmv.24038","volume":"86","author":"L Boglione","year":"2014","unstructured":"Boglione L, Cardellino CS, De Nicolo A, Cariti G, Di Perri G, D'Avolio A. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype a, D and E. J Med Virol. 2014;86(11):1845\u201350.","journal-title":"J Med Virol"},{"issue":"6","key":"3469_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/jmv.25038","volume":"90","author":"L Boglione","year":"2018","unstructured":"Boglione L, Cariti G, Ghisetti V, Burdino E, Di Perri G. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis. J Med Virol. 2018;90(6):1047\u201352.","journal-title":"J Med Virol"},{"issue":"1","key":"3469_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jinf.2014.02.018","volume":"69","author":"L Boglione","year":"2014","unstructured":"Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. The Journal of infection. 2014;69(1):81\u20137.","journal-title":"The Journal of infection"},{"issue":"10","key":"3469_CR35","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/jmv.21588","volume":"81","author":"A Erhardt","year":"2009","unstructured":"Erhardt A, Gobel T, Ludwig A, Lau GK, Marcellin P, van Bommel F, et al. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol. 2009;81(10):1716\u201320.","journal-title":"J Med Virol"},{"issue":"4","key":"3469_CR36","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"3469_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40249-016-0228-4","volume":"6","author":"N Coppola","year":"2017","unstructured":"Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Minichini C, et al. Hepatitis B virus infection in undocumented immigrants and refugees in southern Italy: demographic, virological. and clinical features Infectious diseases of poverty. 2017;6(1):33.","journal-title":"and clinical features Infectious diseases of poverty"},{"issue":"12","key":"3469_CR38","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"issue":"5","key":"3469_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.rce.2016.02.005","volume":"216","author":"JA Cuenca-Gomez","year":"2016","unstructured":"Cuenca-Gomez JA, Salas-Coronas J, Soriano-Perez MJ, Vazquez-Villegas J, Lozano-Serrano AB, Cabezas-Fernandez MT. Viral hepatitis and immigration: a challenge for the healthcare system. Revista clinica espanola. 2016;216(5):248\u201352.","journal-title":"Revista clinica espanola"},{"issue":"2","key":"3469_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association For The Study Of The L","year":"2009","unstructured":"European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227\u201342.","journal-title":"J Hepatol"},{"issue":"1","key":"3469_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The L","year":"2012","unstructured":"European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167\u201385.","journal-title":"J Hepatol"},{"issue":"1","key":"3469_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"2","key":"3469_CR43","first-page":"289","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology. 1996;24(2):289\u201393.","journal-title":"The METAVIR Cooperative Study Group Hepatology"},{"issue":"8388","key":"3469_CR44","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S0140-6736(84)91694-5","volume":"1","author":"JF Botha","year":"1984","unstructured":"Botha JF, Ritchie MJ, Dusheiko GM, Mouton HW, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet. 1984;1(8388):1210\u20132.","journal-title":"Lancet"},{"issue":"2","key":"3469_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4254\/wjh.v2.i2.65","volume":"2","author":"MC Kew","year":"2010","unstructured":"Kew MC. Hepatocellular carcinoma in African blacks: recent progress in etiology and pathogenesis. World J Hepatol. 2010;2(2):65\u201373.","journal-title":"World J Hepatol"},{"issue":"4","key":"3469_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jiph.2015.05.004","volume":"9","author":"C Stasi","year":"2016","unstructured":"Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. Journal of infection and public health. 2016;9(4):389\u201395.","journal-title":"Journal of infection and public health"},{"issue":"10","key":"3469_CR47","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1007\/s10620-015-4027-8","volume":"61","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Zoulim F, Hezode C, Causse X, Roche B, Truchi R, et al. Effectiveness and safety of Tenofovir Disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;61(10):3072\u201383.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"3469_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2009.12.014","volume":"52","author":"S Raimondi","year":"2010","unstructured":"Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010;52(3):441\u20139.","journal-title":"J Hepatol"},{"issue":"10","key":"3469_CR49","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","volume":"61","author":"J Petersen","year":"2016","unstructured":"Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, et al. Effectiveness and safety of Tenofovir Disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci. 2016;61(10):3061\u201371.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3469_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170362","volume":"12","author":"HJ Ahn","year":"2017","unstructured":"Ahn HJ, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK. Treatment efficacy and safety of Tenofovir-based therapy in chronic hepatitis B: a real life cohort study in Korea. PLoS One. 2017;12(1):e0170362.","journal-title":"PLoS One"},{"issue":"4","key":"3469_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1590\/0074-02760150390","volume":"111","author":"CV Pereira","year":"2016","unstructured":"Pereira CV, Tovo CV, Grossmann TK, Mirenda H, Dal-Pupo BB, Almeida PR, et al. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. Memorias do Instituto Oswaldo Cruz. 2016;111(4):252\u20137.","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"issue":"5","key":"3469_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/MEG.0b013e3283511287","volume":"24","author":"M Buti","year":"2012","unstructured":"Buti M, Morillas RM, Prieto M, Diago M, Perez J, Sola R, et al. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2012;24(5):535\u201342.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"3469_CR53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/jvh.12115","volume":"20","author":"JL Hou","year":"2013","unstructured":"Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China. J Viral Hepat. 2013;20(11):811\u201320.","journal-title":"J Viral Hepat"},{"issue":"3","key":"3469_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1665-2681(19)30861-0","volume":"13","author":"E Ridruejo","year":"2014","unstructured":"Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Munoz AE, Adrover R, et al. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naive patients in clinical practice. Ann Hepatol. 2014;13(3):327\u201336.","journal-title":"Ann Hepatol"},{"issue":"3","key":"3469_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/MEG.0b013e32835b3677","volume":"25","author":"A Liu","year":"2013","unstructured":"Liu A, Ha NB, Lin B, Yip B, Trinh HN, Nguyen HA, et al. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. Eur J Gastroenterol Hepatol. 2013;25(3):338\u201343.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"3469_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7150\/ijms.5472","volume":"10","author":"J Luo","year":"2013","unstructured":"Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427\u201333.","journal-title":"Int J Med Sci"},{"issue":"1","key":"3469_CR57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1440-1746.2012.07269.x","volume":"28","author":"CC Wang","year":"2013","unstructured":"Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013;28(1):46\u201350.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"3469_CR58","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3469_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.13440","volume":"43","author":"J Ahn","year":"2016","unstructured":"Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther. 2016;43(1):134\u201344.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3469_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163691","volume":"11","author":"M Pawlowska","year":"2016","unstructured":"Pawlowska M, Domagalski K, Smok B, Rajewski P, Wietlicka-Piszcz M, Halota W, et al. Continuous up to 4 years Entecavir treatment of HBV-infected adolescents - a longitudinal study in real life. PLoS One. 2016;11(9):e0163691.","journal-title":"PLoS One"},{"key":"3469_CR61","first-page":"A1396","volume":"54","author":"INH Carey","year":"2011","unstructured":"Carey INH, Joe D. Denovo antiviral therapy with nucleos(t)ide analogues in \u2018real-life\u2019 patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy. Hepatology. 2011;54:A1396.","journal-title":"Hepatology"},{"issue":"S4","key":"3469_CR62","first-page":"530A","volume":"50","author":"SFYD Baqai","year":"2009","unstructured":"Baqai SFYD, Gish RG. Profound virologic response in chronic hepatitis B (CHB) patients treated with entecavir (ETV) in HBeAg positive and negative disease. Hepatology. 2009;50(S4):530A.","journal-title":"Hepatology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3469-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T06:37:49Z","timestamp":1605422269000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3469-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3469-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,14]]},"assertion":[{"value":"11 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval and consent from the competent Institutional Review Board, namely, <i>Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n de Almer\u00eda<\/i> (Ethics Research Committee of Almeria) on the 1st January 2017, protocol number EPA-E-JAC-2016 version 1. The need for consent was deemed unnecessary by this IRB because the study was carried out within usual clinical practice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JSC participated on one advisory board for Gilead Sciences and received travel grants from Gilead Sciences and Bristol-Myers Squibb. ABLS participated on advisory boards for Bristol-Myers Squibb, and reports travel funding, educational grants and speaker fees from GlaxoSmithKline (ViiV Healthcare), Gilead Sciences, Tibotec (Janssen) Therapeutics, Abbie, Merck Sharp and Dohme, BoehringerIngelheim, Roche Pharma, Pfizer, and Bristol-Myers Squibb. JACG, MJSP and JVV received travel grants from Gilead Sciences. MEE received speaker fees and\/or travel funding from Gilead Sciences, Bristol-Myers Squibb, Abbie, Merck Sharp and Dohme. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"568"}}